MHC
SLXN

Meyer Handelman Company’s Silexion Therapeutics SLXN Stock Holding History

Meyer Handelman Company’s Portfolio SLXN Stock Details SLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-220
Closed -$26.7K – 220
2025
Q2 		$26.7K Hold
220
– – ﹤0.01% 216
2025
Q1 		$36.3K Buy
+220
New +$43.5K ﹤0.01% 213

Other funds holding SLXN

MA
Montag & Associates Atlanta, Georgia $2.15B AUM 20.86% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
PK
Pflug Koory Omaha, Nebraska $250M AUM 42.29% 1-Year Est. Return

Meyer Handelman Company's SLXN Position: Q3 2025 in Review

Meyer Handelman Company sold out of Silexion Therapeutics (SLXN) in Q3 2025, closing a stake of 220 shares — an estimated $26.7K sold.

Meyer Handelman Company first reported a position in SLXN in Q1 2025 and held it in 2 quarters. The position peaked at $36.3K in Q1 2025. 4 funds tracked by Wall St. Rank hold SLXN as of Q3 2025.

  • Meyer Handelman Company reported no remaining Silexion Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Meyer Handelman Company sold 220 Silexion Therapeutics shares in Q3 2025, an estimated $26.7K.
  • Meyer Handelman Company first reported a position in Silexion Therapeutics in Q1 2025 and held it in 2 quarters.
  • Meyer Handelman Company's Silexion Therapeutics position peaked at $36.3K in Q1 2025.
  • 4 funds tracked by Wall St. Rank held Silexion Therapeutics as of Q3 2025.

Based on Meyer Handelman Company's 13F filing for Q3 2025, filed 16 Oct 2025.